Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cadexomer iodine is a topical antiseptic and wound care agent composed of microbeads of cadexomer starch containing 0.9% iodine by weight[5][8]. It is primarily used to clean and promote healing in wet ulcers, chronic wounds, pressure sores, diabetic ulcers, venous leg ulcers, minor burns, cuts, scrapes, and infected surgical or traumatic wounds[1][3][7]. The drug works through a dual mechanism of action: - The hydrophilic beads absorb exudate (wound fluid), pus, slough (dead tissue), and debris from the wound bed[1][8]. - As the beads swell with absorbed fluid, they gradually release iodine into the wound environment. This sustained release provides continuous broad-spectrum antimicrobial activity against bacteria (including MRSA), fungi, viruses, protozoa, and spores[5][6][8]. This combination both cleanses the wound physically and reduces microbial bioburden chemically. Cadexomer iodine also modulates local pH via ion exchange mechanisms in its matrix[6], which may further support healing. Developed in Sweden by Perstorp AB in the early 1980s under the brand name Iodosorb[5], it has been shown to accelerate epidermal regeneration and epithelialization compared to other iodophors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cadexomer iodine.